63664-40-4

Basic information

• Product Name: 3-oxo-N-(tricyclo[3.3.1.1~3,7~]dec-2-yl)butanamide
• Synonyms: CHEMBRDG-BB 6096386;N-2-ADAMANTYL-3-OXOBUTANAMIDE;N-2-adamantyl-3-oxobutanamide(SALTDATA: FREE);Butanamide, 3-oxo-N-tricyclo[3.3.1.13,7]dec-2-yl-
• CAS NO: 63664-40-4
• Molecular Formula: C₁₄H₂₁NO₂
• Molecular Weight: 235.322
• Mol File: 63664-40-4.mol

Chemical Properties

• Melting Point: 97 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 425°C at 760 mmHg
• Flash Point: 169.4°C
• Density: 1.13g/cm³
• Vapor Pressure: 1.98E-07mmHg at 25°C
• Refractive Index: 1.532
• PKA: 11.61±0.46(Predicted)
• CAS DataBase Reference: 3-oxo-N-(tricyclo[3.3.1.1~3,7~]dec-2-yl)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxo-N-(tricyclo[3.3.1.1~3,7~]dec-2-yl)butanamide(63664-40-4)
• EPA Substance Registry System: 3-oxo-N-(tricyclo[3.3.1.1~3,7~]dec-2-yl)butanamide(63664-40-4)

Safety Data

• Hazardous Substances Data: 63664-40-4(Hazardous Substances Data)

Upstream product

• 71189-14-5 (Tricyclo<3.3.1.1^3,7>dec-2-yl)isocyanat 
• 67-64-1 acetone 
• 10523-68-9 adamantan-2-amine hydrochloride 
• 72324-39-1 5-acetyl-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 674-82-8 4-methyleneoxetan-2-one 

Downstream Products

• 1048668-79-6 4-[4-(2-adamantylcarbamoyl)-5-methyl-pyrazol-1-yl]benzoic acid 
• 1048668-80-9 N-(2-adamantyl)-1-(4-cyanophenyl)-5-methyl-pyrazole-4-carboxamide 

Relevant articles and documents

Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: The discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329)

Inhibition of 11β-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome. We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (1) to the development candidate AZD8329 (27). A structural change from pyridine to pyrazole together with structural optimization led to an improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability.

SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281

A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11betaHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS

A compound of formula (I): and pharmaceutically -acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

SYNTHESES AND ANTIBACTERIAL ACTIVITY OF SOME NEW N-(3-METHYL-2-QUINOXALOYL) AMINO ALCOHOLS AND AMINE 1,4-DIOXIDES.

The syntheses and in vitro and in vivo antibacterial activities of a series of N-(3-methyl-2-quinoxaloyl) amino alcohols and amine 1,4-dioxides, and their deoxygenated analogues, are described. The quinoxaline 1,4-dioxide derivative of the naturally occurring ( minus )-ephedrine was found to be the most potent antibacterial agent of the series. The presence of a hydroxy group and a tertiary amide appears to be associated with enhancement of the antibacterial action.